exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087899 RNA Name: hsa-miR-205-5p RNA Type: miRNA Chromosome: chr1 Starnd: + Coordinate: Start Site(bp): 209432166 End Site(bp): 209432187 External Links: hsa-miR-205-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand DOCK6 chr19 11199295 11262524 - MKRN2 chr3 12557087 12583713 + NUP93 chr16 56730118 56850286 + EP300 chr22 41092592 41180077 + CDC42 chr1 22025511 22101360 + LSM1 chr8 38163335 38176730 - TSPYL4 chr6 116249964 116254075 - HINT1 chr5 131159027 131171735 - YTHDF2 chr1 28736621 28769775 + PPP3CC chr8 22440819 22541142 + SLTM chr15 58879050 58933679 - RUNX1T1 chr8 91954967 92103286 - CALM3 chr19 46601074 46610782 + PRKCSH chr19 11435288 11450968 + SFPQ chr1 35176378 35193145 - PLXNA1 chr3 126988594 127037392 + KAZN chr1 13892792 15118043 + OGDH chr7 44606572 44709066 + ZCCHC8 chr12 122471599 122501073 - SLC25A3 chr12 98593591 98606379 + AFF4 chr5 132875395 132963634 - CAPZA2 chr7 116811070 116922049 + SLC3A2 chr11 62856102 62888875 + ACSL1 chr4 184755595 184826818 - XRCC6 chr22 41621119 41664048 + NDUFAF1 chr15 41387353 41402519 - SOSTDC1 chr7 16461481 16530580 - E2F1 chr20 33675477 33686385 - CCZ1B chr7 6794134 6826770 - GNPDA2 chr4 44682200 44726588 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001434 chr4 106345352 106377902 - hsa_circ_0001731 chr7 100731990 100738448 + hsa_circ_0000733 chr17 1561546 1562030 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC009133.5 chr16 29808679 29812227 + GAS5 chr1 173858559 173868882 - MALAT1 chr11 65497688 65506516 + MCM3AP-AS1 chr21 46229196 46259390 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - SNHG16 chr17 76557764 76565348 + SNHG5 chr6 85650491 85678932 - AL356133.1 chr9 26801733 26805862 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.